Cargando…
The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
Approximately 60%–70% of patients with malignant tumours require radiotherapy. The clinical application of immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1, has revolutionized cancer treatment and greatly improved the outcome of a variety of cancers by boosting host immunity.However, rad...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695847/ https://www.ncbi.nlm.nih.gov/pubmed/34956911 http://dx.doi.org/10.3389/fonc.2021.799957 |